{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:47:40Z","timestamp":1792010860910,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AI094189, R01DA041736, DP1DA060602"],"award-info":[{"award-number":["1P30AI094189, R01DA041736, DP1DA060602"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10461-026-05114-5","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:17:17Z","timestamp":1775733437000},"page":"3208-3221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What, how, and when matters: acceptability and preferences for HIV pre-exposure prophylaxis among people who inject drugs in New Delhi, India"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-2931","authenticated-orcid":false,"given":"Allison M.","family":"McFall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose P.","family":"Kaptchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylur K.","family":"Srikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J. C.","family":"Zook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Clipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"5114_CR1","unstructured":"Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim AG et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023."},{"issue":"5","key":"5114_CR2","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","volume":"11","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Global Health. 2023;11(5):e659\u201372.","journal-title":"Lancet Global Health"},{"key":"5114_CR3","unstructured":"UNAIDS. UNAIDS Global AIDS Update. 2022."},{"key":"5114_CR4","unstructured":"UNAIDS. UNAIDS Data. 2018."},{"key":"5114_CR5","unstructured":"UNAIDS. The Gap Report. 2014."},{"issue":"5","key":"5114_CR6","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","volume":"11","author":"S Colledge-Frisby","year":"2023","unstructured":"Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Global Health. 2023;11(5):e673\u201383.","journal-title":"Lancet Global Health"},{"key":"5114_CR7","unstructured":"World Health Organization. Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for people who inject drugs: Policy brief. 2023."},{"issue":"9883","key":"5114_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet"},{"issue":"6","key":"5114_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s10461-024-04308-z","volume":"28","author":"B Suprasert","year":"2024","unstructured":"Suprasert B, Tate M, Reagan D, Ruiz R, Gao K, McNaughton K, et al. Continuing Low Awareness and Use of Pre-exposure Prophylaxis (PrEP) for HIV among People Who Inject Drugs (PWID), San Francisco, 2022. AIDS Behav. 2024;28(6):2089\u2013100.","journal-title":"AIDS Behav"},{"key":"5114_CR10","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.dadr.2024.100288","volume":"13","author":"T Verinumbe","year":"2024","unstructured":"Verinumbe T, Lucas GM, Zook K, Weir B, Landry M, Page KR, et al. Associations of HIV pre-exposure prophylaxis (PrEP) indication, HIV risk perception and unwillingness to use PrEP among people who inject drugs in Baltimore, MD. Drug Alcohol Depend Rep. 2024;13:100288.","journal-title":"Drug Alcohol Depend Rep"},{"key":"5114_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-018-0263-5","volume":"15","author":"K Biello","year":"2018","unstructured":"Biello K, Bazzi A, Mimiaga M, Biancarelli D, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15:1\u201312.","journal-title":"Harm Reduct J"},{"key":"5114_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s10461-014-0867-z","volume":"19","author":"DJ Escudero","year":"2015","unstructured":"Escudero DJ, Kerr T, Wood E, Nguyen P, Lurie MN, Sued O, et al. Acceptability of HIV Pre-exposure Prophylaxis (P r EP) Among People Who Inject Drugs (PWID) in a Canadian Setting. AIDS Behav. 2015;19:752\u20137.","journal-title":"AIDS Behav"},{"issue":"5","key":"5114_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","volume":"25","author":"CB Mistler","year":"2021","unstructured":"Mistler CB, Copenhaver MM, Shrestha R. The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. AIDS Behav. 2021;25(5):1490\u2013506.","journal-title":"AIDS Behav"},{"key":"5114_CR14","unstructured":"World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. 2022."},{"key":"5114_CR15","unstructured":"World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Geneva; 2025."},{"issue":"7","key":"5114_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"10337","key":"5114_CR17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"13","key":"5114_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Karim QA, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024;391(13):1179\u201392.","journal-title":"N Engl J Med"},{"key":"5114_CR19","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J et al. Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Gay, Bisexual, and Other Men, Transgender Women, Transgender Men, and Gender-Nonbinary People who Have Sex With Partners Assigned Male at Birth: Interim Analysis Results From the PURPOSE 2 Study. HIVR49 2024; Lima, Peru2024."},{"key":"5114_CR20","unstructured":"Gilead Sciences. Study of Lenacapavir and Emtricitabine\/\u200bTenofovir Disoproxil Fumarate (F\/\u200bTDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) (PURPOSE 4) 2025 [Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06101342"},{"issue":"7","key":"5114_CR21","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","volume":"6","author":"BR Bavinton","year":"2021","unstructured":"Bavinton BR, Grulich AE. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public Health. 2021;6(7):e528\u201333.","journal-title":"Lancet Public Health"},{"key":"5114_CR22","volume-title":"Magnitude of substance use in India","author":"A Ambekar","year":"2019","unstructured":"Ambekar A, Agrawal A, Rao R, Mishra AK, Khandelwal SK, Chadda RK. Magnitude of substance use in India. New Delhi: Ministry of Social Justice and Empowerment, Government of India; 2019."},{"issue":"12","key":"5114_CR23","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Global Health"},{"key":"5114_CR24","unstructured":"National AIDS Control Organisation, Sankalak. Status of National AIDS & STD Respoonse, Sixth Edition (2024). 2024."},{"issue":"1","key":"5114_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1186\/s12889-022-13922-2","volume":"22","author":"LN Pachuau","year":"2022","unstructured":"Pachuau LN, Tannous C, Dhami MV, Agho KE. HIV among people who inject drugs in India: a systematic review. BMC Public Health. 2022;22(1):1529.","journal-title":"BMC Public Health"},{"issue":"42","key":"5114_CR26","doi-asserted-by":"publisher","first-page":"eabf0158","DOI":"10.1126\/sciadv.abf0158","volume":"8","author":"SJ Clipman","year":"2022","unstructured":"Clipman SJ, Mehta SH, Mohapatra S, Srikrishnan AK, Zook KJC, Duggal P, et al. Deep learning and social network analysis elucidate drivers of HIV transmission in a high-incidence cohort of people who inject drugs. Sci Adv. 2022;8(42):eabf0158.","journal-title":"Sci Adv"},{"issue":"9","key":"5114_CR27","doi-asserted-by":"publisher","first-page":"e26361","DOI":"10.1002\/jia2.26361","volume":"27","author":"AM McFall","year":"2024","unstructured":"McFall AM, Gunaratne MP, Ganapathi L, Srikrishnan AK, Vasudevan CK, Anand S, et al. Persistently high HIV incidence among men who have sex with men and people who inject drugs attending integrated care centres in India: a longitudinal assessment of clinic-based data. J Int AIDS Soc. 2024;27(9):e26361.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"5114_CR28","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2352-3018(21)00098-9","volume":"8","author":"EU Patel","year":"2021","unstructured":"Patel EU, Solomon SS, Lucas GM, McFall AM, Srikrishnan AK, Kumar MS, et al. Temporal change in population-level prevalence of detectable HIV viraemia and its association with HIV incidence in key populations in India: a serial cross-sectional study. Lancet HIV. 2021;8(9):e544\u201353.","journal-title":"Lancet HIV"},{"key":"5114_CR29","volume-title":"Strategy Document: National AIDS and STD Control Programme Phase-V (2021-26)","author":"National AIDS Control Organisation","year":"2022","unstructured":"National AIDS Control Organisation. Strategy Document: National AIDS and STD Control Programme Phase-V (2021-26). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2022."},{"issue":"5","key":"5114_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/QAD.0000000000000592","volume":"29","author":"GM Lucas","year":"2015","unstructured":"Lucas GM, Solomon SS, Srikrishnan AK, Agrawal A, Iqbal S, Laeyendecker O, et al. High HIV burden among people who inject drugs in 15 Indian cities. AIDS. 2015;29(5):619\u201328.","journal-title":"AIDS"},{"issue":"1","key":"5114_CR31","doi-asserted-by":"publisher","first-page":"e0169482","DOI":"10.1371\/journal.pone.0169482","volume":"12","author":"B Sabri","year":"2017","unstructured":"Sabri B, McFall AM, Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, et al. Gender Differences in Factors Related to HIV Risk Behaviors among People Who Inject Drugs in North-East India. PLoS ONE. 2017;12(1):e0169482.","journal-title":"PLoS ONE"},{"key":"5114_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drugpo.2018.02.007","volume":"57","author":"MK Smith","year":"2018","unstructured":"Smith MK, Solomon SS, Cummings DAT, Srikrishnan AK, Kumar MS, Vasudevan CK, et al. Overlap between harm reduction and HIV service utilisation among PWID in India: Implications for HIV combination prevention. Int J Drug Policy. 2018;57:111\u20138.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"5114_CR33","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2352-3018(19)30034-7","volume":"6","author":"SS Solomon","year":"2019","unstructured":"Solomon SS, Solomon S, McFall AM, Srikrishnan AK, Anand S, Verma V, et al. Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial. Lancet HIV. 2019;6(5):e283\u201396.","journal-title":"Lancet HIV"},{"key":"5114_CR34","unstructured":"National AIDS Control Organisation. National Technical Guidelines for Pre-Exposure Prophylaxis. NACO, Ministry of Health and Family Welfare, Government of India; 2022."},{"issue":"6","key":"5114_CR35","first-page":"527","volume":"160","author":"A Gaur","year":"2024","unstructured":"Gaur A, Rakhmanina N. What will it take to expand the pre-exposure prophylaxis to prevent new HIV infections in India? Indian J Med Res. 2024;160(6):527\u20139.","journal-title":"Indian J Med Res"},{"key":"5114_CR36","unstructured":"PrEPWatch. The Global PrEP Tracker: Country Overview - India [Available from: https:\/\/data.prepwatch.org\/"},{"key":"5114_CR37","unstructured":"Medicines Patent Pool signs sublicences with Aurobindo. Cipla and Viatris to produce generic versions of ViiV Healthcare\u2019s innovative long-acting HIV prevention medicine [press release]. 2023."},{"key":"5114_CR38","unstructured":"Unitaid, Unitaid. CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy\u2019s to make HIV prevention tool lenacapavir affordable in LMICs: World Health Organization; 2025 [Available from: https:\/\/unitaid.org\/news-blog\/lenacapavir-for-hiv-prevention\/"},{"key":"5114_CR39","unstructured":"Ripin D. Approach to delivery of LA ARVs for HIV treatment and Prevention in LMICs \u2013 Cabotegravir as a precedent-setting case study. Long-Acting\/Extended Release Antiviral Research Resource Program (LEAP) Investigator Meeting and Annual Workshop; 2022."},{"issue":"6","key":"5114_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17441692.2020.1724316","volume":"15","author":"S Reza-Paul","year":"2020","unstructured":"Reza-Paul S, Lazarus L, Maiya R, Haldar P, Rewari B, Venugopal M, et al. The Ashodaya PrEP project: Lessons and implications for scaling up PrEP from a community-led demonstration project among female sex workers in Mysore, India. Glob Public Health. 2020;15(6):889\u2013904.","journal-title":"Glob Public Health"},{"issue":"7","key":"5114_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0956462420983992","volume":"32","author":"S Jana","year":"2021","unstructured":"Jana S, Ray P, Roy S, Kadam A, Gangakhedkar RR, Rewari B, et al. Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. Int J STD AIDS. 2021;32(7):638\u201347.","journal-title":"Int J STD AIDS"},{"key":"5114_CR42","unstructured":"Bharucha S, Parthasarathy, Salvat M, McFall AM, Bell J, Okram S et al. Non-HIV entry points to deliver HIV services to transgender women in India (Poster #941). Conference on Retroviruses and Opportunistic Infections; Seattle, WA. 2023."},{"issue":"2","key":"5114_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/apc.2019.0237","volume":"34","author":"V Chakrapani","year":"2020","unstructured":"Chakrapani V, Shunmugam M, Rawat S, Baruah D, Nelson R, Newman PA. Acceptability of HIV pre-exposure prophylaxis among transgender women in India: a qualitative investigation. AIDS Patient Care STDs. 2020;34(2):92\u20138.","journal-title":"AIDS Patient Care STDs"},{"issue":"2","key":"5114_CR44","doi-asserted-by":"publisher","first-page":"e0281984","DOI":"10.1371\/journal.pone.0281984","volume":"18","author":"S Ramanaik","year":"2023","unstructured":"Ramanaik S, Sinha AP, Mukherjee A, Pujar A, Subramanyam K, Gopalan A, et al. Acceptability of PrEP among MSM and transgender communities\u2014Qualitative findings from two metropolitan cities in India. PLoS ONE. 2023;18(2):e0281984.","journal-title":"PLoS ONE"},{"issue":"3","key":"5114_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/09540121.2021.1887801","volume":"34","author":"V Chakrapani","year":"2022","unstructured":"Chakrapani V, Newman PA, Shunmugam M, Rawat S, Baruah D, Nelson R, et al. PrEP eligibility, HIV risk perception, and willingness to use PrEP among high-risk men who have sex with men in India: A cross-sectional survey. AIDS Care. 2022;34(3):301\u20139.","journal-title":"AIDS Care"},{"key":"5114_CR46","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1007\/s10461-021-03253-5","volume":"25","author":"V Chakrapani","year":"2021","unstructured":"Chakrapani V, Newman PA, Cameron M, Shunmugam M, Roungprakhon S, Rawat S, et al. Willingness to use pre-exposure prophylaxis (PrEP) and preferences among men who have sex with men in Mumbai and Chennai, India: a discrete choice experiment. AIDS Behav. 2021;25:3074\u201384.","journal-title":"AIDS Behav"},{"issue":"2","key":"5114_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1089\/trgh.2019.0076","volume":"6","author":"V Chakrapani","year":"2021","unstructured":"Chakrapani V, Shaikh S, Arumugam V, Chawla U, Mehta S. Factors Influencing Willingness to Use Human Immunodeficiency Virus Preexposure Prophylaxis Among Transgender Women in India. Transgender health. 2021;6(2):64\u201373.","journal-title":"Transgender health"},{"issue":"2","key":"5114_CR48","doi-asserted-by":"publisher","first-page":"e0247352","DOI":"10.1371\/journal.pone.0247352","volume":"16","author":"A Belludi","year":"2021","unstructured":"Belludi A, McFall AM, Solomon SS, Celentano DD, Mehta SH, Srikrishnan A, et al. Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey. PLoS ONE. 2021;16(2):e0247352.","journal-title":"PLoS ONE"},{"key":"5114_CR49","doi-asserted-by":"publisher","first-page":"e69174","DOI":"10.7554\/eLife.69174","volume":"10","author":"SJ Clipman","year":"2021","unstructured":"Clipman SJ, Mehta SH, Srikrishnan AK, Zook KJC, Duggal P, Mohapatra S, et al. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India. eLife. 2021;10:e69174.","journal-title":"eLife"},{"key":"5114_CR50","unstructured":"Creswell JW, Clark VLP. Designing and conducting mixed methods research. Sage; 2017."},{"key":"5114_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-4020-5753-3_1","volume-title":"Using Discrete Choice Experiments to Value Health and Health Care","author":"M Ryan","year":"2008","unstructured":"Ryan M, Gerard K, Amaya-Amaya M. Discrete Choice Experiments in a Nutshell. In: Ryan M, Gerard K, Amaya-Amaya M, editors. Using Discrete Choice Experiments to Value Health and Health Care. Dordrecht: Springer Netherlands; 2008. pp. 13\u201346."},{"key":"5114_CR52","unstructured":"WHO. How to Conduct a Discrete Choice Experiment for Health Workforce Recruitment and Retention in Remote and Rural Areas: A User Guide with Case Studies. WHO; 2012."},{"key":"5114_CR53","volume-title":"_R: A Language and Environment for Statistical Computing_","author":"R Core Team","year":"2025","unstructured":"R Core Team. _R: A Language and Environment for Statistical Computing_. Vienna, Austria: R Foundation for Statistical Computing; 2025."},{"issue":"4","key":"5114_CR54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, et al. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"issue":"12","key":"5114_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/apc.2018.0126","volume":"32","author":"AR Bazzi","year":"2018","unstructured":"Bazzi AR, Biancarelli DL, Childs E, Drainoni M-L, Edeza A, Salhaney P, et al. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Patient Care STDs. 2018;32(12):529\u201337.","journal-title":"AIDS Patient Care STDs"},{"key":"5114_CR56","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.jsat.2020.108058","volume":"117","author":"R Shrestha","year":"2020","unstructured":"Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. J Subst Abuse Treat. 2020;117:108058.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"5114_CR57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13722-024-00478-2","volume":"19","author":"JL Merle","year":"2024","unstructured":"Merle JL, Zapata JP, Quieroz A, Zamantakis A, Sanuade O, Mustanski B, et al. Pre-exposure prophylaxis (PrEP) among people who use drugs: a qualitative scoping review of implementation determinants and change methods. Addict Sci Clin Pract. 2024;19(1):46.","journal-title":"Addict Sci Clin Pract"},{"key":"5114_CR58","unstructured":"HIV.gov. Pre-exposure prophylaxis 2025 [Available from: https:\/\/www.hiv.gov\/hiv-basics\/hiv-prevention\/using-hiv-medication-to-reduce-risk\/pre-exposure-prophylaxis"},{"issue":"1","key":"5114_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11904-020-00535-w","volume":"18","author":"WC Sewell","year":"2021","unstructured":"Sewell WC, Solleveld P, Seidman D, Dehlendorf C, Marcus JL, Krakower DS. Patient-Led Decision-Making for HIV Preexposure Prophylaxis. Curr HIV\/AIDS Rep. 2021;18(1):48\u201356.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"7","key":"5114_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/apc.2024.0078","volume":"38","author":"S Goswami","year":"2024","unstructured":"Goswami S, Borate S, Marupuru S, Marupuru S. A Scoping Review of the Current Landscape of Pre-Exposure Prophylaxis and Postexposure Prophylaxis in India. AIDS Patient Care STDs. 2024;38(7):287\u2013304.","journal-title":"AIDS Patient Care STDs"},{"key":"5114_CR61","doi-asserted-by":"publisher","first-page":"e5945","DOI":"10.1136\/bmj.e5945","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.","journal-title":"BMJ"},{"key":"5114_CR62","unstructured":"United Nations Office on Drugs and Crime. Opioid Substitution - Buprenorphine in India. 2010."},{"key":"5114_CR63","doi-asserted-by":"publisher","first-page":"111133","DOI":"10.1016\/j.drugalcdep.2024.111133","volume":"257","author":"MA Hatch","year":"2024","unstructured":"Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, et al. PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high. Drug Alcohol Depend. 2024;257:111133.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"5114_CR64","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","volume":"37","author":"VA Fonner","year":"2023","unstructured":"Fonner VA, Ridgeway K, van der Straten A, Lorenzetti L, Dinh N, Rodolph M, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957\u201366.","journal-title":"AIDS"},{"issue":"5","key":"5114_CR65","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","volume":"19","author":"UM Parikh","year":"2022","unstructured":"Parikh UM, Koss CA, Mellors JW. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance? Curr HIV\/AIDS Rep. 2022;19(5):384\u201393.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"5114_CR66","doi-asserted-by":"crossref","unstructured":"van Zyl G, Prochazka M, Schmidt HA, Orrell C, Schapiro JM, McCluskey SM et al. Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis. Lancet HIV. 2025.","DOI":"10.1016\/S2352-3018(25)00128-6"},{"issue":"6","key":"5114_CR67","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","volume":"79","author":"KM Gibas","year":"2019","unstructured":"Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug Resistance During HIV Pre-Exposure Prophylaxis. Drugs. 2019;79(6):609\u201319.","journal-title":"Drugs"},{"issue":"1","key":"5114_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13722-024-00505-2","volume":"19","author":"WH Eger","year":"2024","unstructured":"Eger WH, Bazzi AR, Valasek CJ, Vera CF, Harvey-Vera A, Strathdee SA, et al. HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment. Addict Sci Clin Pract. 2024;19(1):81.","journal-title":"Addict Sci Clin Pract"},{"key":"5114_CR69","unstructured":"Kapoor Y, Evans B, Carstens RP, Diamond TL, Grandhi A, Gillespie G, MK-8527 PK\/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis. Conference on Retroviruses and, Infections O et al. (CROI); March 9\u201312, 2025; San Francisco, California2025."},{"key":"5114_CR70","unstructured":"Merck S, Dohme LLC. A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) 2025 [updated September 18, 2025. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT07044297"},{"issue":"2","key":"5114_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/20479700.2019.1665882","volume":"14","author":"SK Rout","year":"2021","unstructured":"Rout SK, Sahu KS, Mahapatra S. Utilization of health care services in public and private healthcare in India: Causes and determinants. Int J Healthc Manag. 2021;14(2):509\u201316.","journal-title":"Int J Healthc Manag"},{"issue":"11","key":"5114_CR72","doi-asserted-by":"publisher","first-page":"e25636","DOI":"10.1002\/jia2.25636","volume":"23","author":"CL Celum","year":"2020","unstructured":"Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23(11):e25636.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"5114_CR73","doi-asserted-by":"publisher","first-page":"e10448","DOI":"10.2196\/10448","volume":"7","author":"S LeGrand","year":"2018","unstructured":"LeGrand S, Knudtson K, Benkeser D, Muessig K, Mcgee A, Sullivan PS, et al. Testing the efficacy of a social networking gamification app to improve pre-exposure prophylaxis adherence (P3: Prepared, Protected, emPowered): protocol for a randomized controlled trial. JMIR Res protocols. 2018;7(12):e10448.","journal-title":"JMIR Res protocols"},{"issue":"5","key":"5114_CR74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11904-022-00624-y","volume":"19","author":"U Roy Paladhi","year":"2022","unstructured":"Roy Paladhi U, Katz DA, Farquhar C, Thirumurthy H. Using Behavioral Economics to Support PrEP Adherence for HIV Prevention. Curr HIV\/AIDS Rep. 2022;19(5):409\u201314.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"5114_CR75","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10461-021-03443-1","volume":"26","author":"A Salinas-Rodr\u00edguez","year":"2022","unstructured":"Salinas-Rodr\u00edguez A, Sosa-Rub\u00ed SG, Chivardi C, Rodr\u00edguez-Franco R, Gandhi M, Mayer KH, et al. Preferences for conditional economic incentives to improve pre-exposure prophylaxis adherence: a discrete choice experiment among male sex workers in Mexico. AIDS Behav. 2022;26(3):833\u201342.","journal-title":"AIDS Behav"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05114-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:12:30Z","timestamp":1792008750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5114"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05114-5","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"19 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Johns Hopkins Medicine and YRGCARE Institutional Review Boards reviewed and approved this research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FGD participants provided oral consent following a brief description of the purpose of the discussion and what they were being asked to do. Spatial Network Study cohort participants provided written consent for study participation following a detailed description of the purpose of the study and what they were being asked to do.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shruti H Mehta has received materials support from Abbott Diagnostics. Sunil S Solomon serves as the Managing Trustee of the YR Gaitonde Medical Education Research Foundation and on the Board of Directors of the Serious Fun Children\u2019s Network. Sunil S Solomon has also received grants, product, and honoraria from Abbott Laboratories and Gilead Sciences not related to the work presented in the manuscript. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}